265 related articles for article (PubMed ID: 33910928)
1. Multilevel Regulation of β-Catenin Activity by SETD2 Suppresses the Transition from Polycystic Kidney Disease to Clear Cell Renal Cell Carcinoma.
Rao H; Li X; Liu M; Liu J; Feng W; Tang H; Xu J; Gao WQ; Li L
Cancer Res; 2021 Jul; 81(13):3554-3567. PubMed ID: 33910928
[TBL] [Abstract][Full Text] [Related]
2. SETD2 deficiency accelerates sphingomyelin accumulation and promotes the development of renal cancer.
Rao H; Liu C; Wang A; Ma C; Xu Y; Ye T; Su W; Zhou P; Gao WQ; Li L; Ding X
Nat Commun; 2023 Nov; 14(1):7572. PubMed ID: 37989747
[TBL] [Abstract][Full Text] [Related]
3. SOX6 represses tumor growth of clear cell renal cell carcinoma by HMG domain-dependent regulation of Wnt/β-catenin signaling.
Chen L; Xie Y; Ma X; Zhang Y; Li X; Zhang F; Gao Y; Fan Y; Gu L; Wang L; Zhang X; Fu B
Mol Carcinog; 2020 Oct; 59(10):1159-1173. PubMed ID: 32794610
[TBL] [Abstract][Full Text] [Related]
4. High-resolution profiling of histone h3 lysine 36 trimethylation in metastatic renal cell carcinoma.
Ho TH; Park IY; Zhao H; Tong P; Champion MD; Yan H; Monzon FA; Hoang A; Tamboli P; Parker AS; Joseph RW; Qiao W; Dykema K; Tannir NM; Castle EP; Nunez-Nateras R; Teh BT; Wang J; Walker CL; Hung MC; Jonasch E
Oncogene; 2016 Mar; 35(12):1565-74. PubMed ID: 26073078
[TBL] [Abstract][Full Text] [Related]
5.
Su X; Zhang J; Mouawad R; Compérat E; Rouprêt M; Allanic F; Parra J; Bitker MO; Thompson EJ; Gowrishankar B; Houldsworth J; Weinstein JN; Tost J; Broom BM; Khayat D; Spano JP; Tannir NM; Malouf GG
Cancer Res; 2017 Sep; 77(18):4835-4845. PubMed ID: 28754676
[TBL] [Abstract][Full Text] [Related]
6. PRMT7 promotes the growth of renal cell carcinoma through modulating the β-catenin/C-MYC axis.
Liu F; Wan L; Zou H; Pan Z; Zhou W; Lu X
Int J Biochem Cell Biol; 2020 Mar; 120():105686. PubMed ID: 31926310
[TBL] [Abstract][Full Text] [Related]
7. Functional Studies on Primary Tubular Epithelial Cells Indicate a Tumor Suppressor Role of SETD2 in Clear Cell Renal Cell Carcinoma.
Li J; Kluiver J; Osinga J; Westers H; van Werkhoven MB; Seelen MA; Sijmons RH; van den Berg A; Kok K
Neoplasia; 2016 Jun; 18(6):339-46. PubMed ID: 27292023
[TBL] [Abstract][Full Text] [Related]
8. SETD2 mutation in renal clear cell carcinoma suppress autophagy via regulation of ATG12.
González-Rodríguez P; Engskog-Vlachos P; Zhang H; Murgoci AN; Zerdes I; Joseph B
Cell Death Dis; 2020 Jan; 11(1):69. PubMed ID: 31988284
[TBL] [Abstract][Full Text] [Related]
9. Loss of SETD2, but not H3K36me3, correlates with aggressive clinicopathological features of clear cell renal cell carcinoma patients.
Liu L; Guo R; Zhang X; Liang Y; Kong F; Wang J; Xu Z
Biosci Trends; 2017 May; 11(2):214-220. PubMed ID: 28260718
[TBL] [Abstract][Full Text] [Related]
10. Histone methyltransferase SETD2 regulates osteosarcoma cell growth and chemosensitivity by suppressing Wnt/β-catenin signaling.
Jiang C; He C; Wu Z; Li F; Xiao J
Biochem Biophys Res Commun; 2018 Jul; 502(3):382-388. PubMed ID: 29842882
[TBL] [Abstract][Full Text] [Related]
11. SETD2 loss in renal epithelial cells drives epithelial-to-mesenchymal transition in a TGF-β-independent manner.
Wang T; Wagner RT; Hlady RA; Pan X; Zhao X; Kim S; Wang L; Lee JH; Luo H; Castle EP; Lake DF; Ho TH; Robertson KD
Mol Oncol; 2024 Jan; 18(1):44-61. PubMed ID: 37418588
[TBL] [Abstract][Full Text] [Related]
12. MCPIP1 inhibits Wnt/β-catenin signaling pathway activity and modulates epithelial-mesenchymal transition during clear cell renal cell carcinoma progression by targeting miRNAs.
Gorka J; Marona P; Kwapisz O; Waligórska A; Pospiech E; Dobrucki JW; Rys J; Jura J; Miekus K
Oncogene; 2021 Dec; 40(50):6720-6735. PubMed ID: 34657130
[TBL] [Abstract][Full Text] [Related]
13. Integrated Genomic and Proteomic Analyses Reveal Novel Mechanisms of the Methyltransferase SETD2 in Renal Cell Carcinoma Development.
Li L; Miao W; Huang M; Williams P; Wang Y
Mol Cell Proteomics; 2019 Mar; 18(3):437-447. PubMed ID: 30487242
[TBL] [Abstract][Full Text] [Related]
14. NLRC5 mediates cell proliferation, migration, and invasion by regulating the Wnt/β-catenin signalling pathway in clear cell renal cell carcinoma.
Wang Q; Ding H; He Y; Li X; Cheng Y; Xu Q; Yang Y; Liao G; Meng X; Huang C; Li J
Cancer Lett; 2019 Mar; 444():9-19. PubMed ID: 30543814
[TBL] [Abstract][Full Text] [Related]
15. miR-106b-5p targets tumor suppressor gene SETD2 to inactive its function in clear cell renal cell carcinoma.
Xiang W; He J; Huang C; Chen L; Tao D; Wu X; Wang M; Luo G; Xiao X; Zeng F; Jiang G
Oncotarget; 2015 Feb; 6(6):4066-79. PubMed ID: 25714014
[TBL] [Abstract][Full Text] [Related]
16. β-catenin ablation exacerbates polycystic kidney disease progression.
Conduit SE; Hakim S; Feeney SJ; Ooms LM; Dyson JM; Abud HE; Mitchell CA
Hum Mol Genet; 2019 Jan; 28(2):230-244. PubMed ID: 30265301
[TBL] [Abstract][Full Text] [Related]
17. WNT10A plays an oncogenic role in renal cell carcinoma by activating WNT/β-catenin pathway.
Hsu RJ; Ho JY; Cha TL; Yu DS; Wu CL; Huang WP; Chu P; Chen YH; Chen JT; Yu CP
PLoS One; 2012; 7(10):e47649. PubMed ID: 23094073
[TBL] [Abstract][Full Text] [Related]
18. Decreased Expression of SETD2 Predicts Unfavorable Prognosis in Patients With Nonmetastatic Clear-Cell Renal Cell Carcinoma.
Liu W; Fu Q; An H; Chang Y; Zhang W; Zhu Y; Xu L; Xu J
Medicine (Baltimore); 2015 Nov; 94(45):e2004. PubMed ID: 26559293
[TBL] [Abstract][Full Text] [Related]
19. Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network.
Hakimi AA; Ostrovnaya I; Reva B; Schultz N; Chen YB; Gonen M; Liu H; Takeda S; Voss MH; Tickoo SK; Reuter VE; Russo P; Cheng EH; Sander C; Motzer RJ; Hsieh JJ;
Clin Cancer Res; 2013 Jun; 19(12):3259-67. PubMed ID: 23620406
[TBL] [Abstract][Full Text] [Related]
20.
Chiang YC; Park IY; Terzo EA; Tripathi DN; Mason FM; Fahey CC; Karki M; Shuster CB; Sohn BH; Chowdhury P; Powell RT; Ohi R; Tsai YS; de Cubas AA; Khan A; Davis IJ; Strahl BD; Parker JS; Dere R; Walker CL; Rathmell WK
Cancer Res; 2018 Jun; 78(12):3135-3146. PubMed ID: 29724720
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
